piritrexim

RN given refers to parent cpd; structure given in first source

Also Known As:

2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido(2,3-d)pyrimidine; BW 301U; BW-301U; BW301U; piritrexim monohydrochloride; Pyrido(2,3-d)pyrimidine-2,4-diamine, 6-((2,5-dimethoxyphenyl)methyl)-5-methyl-

Networked: 40 relevant articles (3 outcomes, 19 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - piritrexim: 40

Experts

1.	Wilding, George: 3 articles (12/2005 - 11/2002)
2.	Liu, Glenn: 2 articles (12/2005 - 06/2003)
3.	Marnocha, Rebecca: 2 articles (12/2005 - 06/2003)
4.	Queener, Sherry F: 2 articles (05/2004 - 04/2003)
5.	Rosowsky, Andre: 2 articles (05/2004 - 04/2003)
6.	Carducci, Michael A: 1 article (03/2008)
7.	Hussain, Maha H: 1 article (03/2008)
8.	Lassiter, Lance K: 1 article (03/2008)
9.	Petrylak, Daniel P: 1 article (03/2008)
10.	Stadler, Walter M: 1 article (03/2008)

Related Diseases

1.	Psoriasis (Pustulosis Palmaris et Plantaris) 04/01/1991 - "Since it is not polyglutamated, piritrexim could be effective in the treatment of psoriasis without the associated long-term hepatotoxicity. " 11/01/1993 - "An open, 12-week, multicentre study was conducted to assess the efficacy of piritrexim isethionate in the treatment of severe psoriasis. " 04/01/1991 - "Piritrexim is efficacious in the treatment of psoriasis." 11/01/1993 - "Piritrexim appears to be an effective therapy for severe psoriasis at doses of 300 and 450 mg weekly, in three divided doses over 36 h." 04/01/1991 - "A 12-week phase I/II clinical trial of severe chronic plaque psoriasis assessed the safety and efficacy of oral piritrexim therapy. "
2.	Neoplasms (Cancer) 02/01/1993 - "Oral piritrexim, an effective treatment for metastatic urothelial cancer." 11/01/1999 - "In March 1995, ILEX acquired an exclusive, worldwide license to patents held by Burroughs Wellcome covering the composition and use of piritrexim for all cancer indications. " 02/01/1993 - "We conclude that piritrexim appears to be an active agent in patients with metastatic urothelial cancer when administered as a 5-day, low-dose oral schedule. " 01/01/1985 - "As part of a Phase I evaluation of this agent we studied normal bone marrow from cancer patients and their metabolic susceptibility to either BW 301U or to MTX and then repeated the observations at the end of five days of BW 301U infusions. " 02/01/1993 - "We performed a phase II study with oral piritrexim in non-chemotherapy pretreated patients with metastatic urothelial cancer. "
3.	Head and Neck Neoplasms (Head and Neck Cancer) 02/15/1992 - "A phase II study of piritrexim in patients with advanced squamous head and neck cancer." 05/01/1991 - "A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer." 05/01/1991 - "Thirty patients with recurrent and/or metastatic head and neck cancer were treated with sequentially administered methotrexate (MTX) and piritrexim (PTX). " 01/01/1992 - "Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach."
4.	Urinary Bladder Neoplasms (Bladder Cancer) 11/01/1999 - "ILEX conducted phase II clinical trials in the US and Europe with piritrexim in bladder cancer patients; however, development for this indication was discontinued in the third quarter of 1998 due to lack of efficacy. " 01/01/1997 - "Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder." 11/01/1999 - "In published phase II studies, piritrexim demonstrated objective response rates ranging from 23 to 75% in patients with advanced bladder cancer who failed a standard first-line chemotherapy regimen. " 10/01/1994 - "Piritrexim may be an effective drug for bladder cancer after progression on MVAC chemotherapy." 10/01/1994 - "Four patients with advanced or metastatic bladder cancer progressing after MVAC chemotherapy were treated with oral piritrexim. "
5.	Melanoma (Melanoma, Malignant) 03/01/1991 - "Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration." 12/01/1995 - "Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma." 12/01/1995 - "A Phase II trial was conducted in patients with metastatic malignant melanoma with DTIC 250 mg/m2 intravenously for 5 days alternating monthly with Piritrexim (PTX) using an intermittent, low-dose oral administration schedule. " 03/01/1991 - "A phase II trial of piritrexim (2,4-diamino-6[2,5-dimethoxybenzyl]-5-methyl pyrido-[2,3d] pyrimidine, 301U74; PTX) was conducted for patients with metastatic malignant melanoma using an intermittent, low-dose oral administration schedule. "

Related Drugs and Biologics

1.	piritrexim
2.	Methotrexate (Mexate)
3.	Trimetrexate (JB11)
4.	Lipids
5.	pyrimidine
6.	Folic Acid (Vitamin M)
7.	Dacarbazine (DIC)
8.	Antimetabolites
9.	Gemcitabine
10.	Folic Acid Antagonists

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Oral Administration
4.	Chemoradiotherapy